Author Correction: Genomic characterization of metastatic breast cancers.

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
Aug 2019
Historique:
pubmed: 17 7 2019
medline: 17 7 2019
entrez: 17 7 2019
Statut: ppublish

Résumé

An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiants

DOI: 10.1038/s41586-019-1380-3 PMID: 31308536
pubmed: 31308536
doi: 10.1038/s41586-019-1380-3
pii: 10.1038/s41586-019-1380-3
doi:

Types de publication

Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

E7

Commentaires et corrections

Type : ErratumFor

Auteurs

François Bertucci (F)

CRCM, Predictive Oncology team, Inserm, Aix-Marseille Univ, CNRS, Institut Paoli-Calmettes, Marseille, France. fandre@igr.fr.

Charlotte K Y Ng (CKY)

Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland.
Department for BioMedical Research, University of Bern, Bern, Switzerland.

Anne Patsouris (A)

Inserm, U1232, Nantes, France.
Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France.

Nathalie Droin (N)

Genomic Core Facility UMS AMMICA Gustave Roussy Cancer Campus, Villejuif, France.
INSERM, US23, Villejuif, France.
CNRS, UMS3665, Villejuif, France.

Salvatore Piscuoglio (S)

Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Clarunis, Department of Biomedicine, University of Basel, Basel, Switzerland.

Nadine Carbuccia (N)

CRCM, Predictive Oncology team, Inserm, Aix-Marseille Univ, CNRS, Institut Paoli-Calmettes, Marseille, France.

Jean Charles Soria (JC)

Université Paris Sud, Orsay, France.
Drug Development Department (DITEP), Gustave Roussy Cancer Campus, Villejuif, France.

Alicia Tran Dien (AT)

Bioinformatics Core Facility, Gustave Roussy Cancer Campus, Villejuif, France.

Yahia Adnani (Y)

Bioinformatics Core Facility, Gustave Roussy Cancer Campus, Villejuif, France.

Maud Kamal (M)

Department of Translational Research, Institut Curie, Saint-Cloud, France.

Séverine Garnier (S)

CRCM, Predictive Oncology team, Inserm, Aix-Marseille Univ, CNRS, Institut Paoli-Calmettes, Marseille, France.

Guillaume Meurice (G)

Bioinformatics Core Facility, Gustave Roussy Cancer Campus, Villejuif, France.

Marta Jimenez (M)

Unicancer, Paris, France.

Semih Dogan (S)

Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France.

Benjamin Verret (B)

Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France.

Max Chaffanet (M)

CRCM, Predictive Oncology team, Inserm, Aix-Marseille Univ, CNRS, Institut Paoli-Calmettes, Marseille, France.

Thomas Bachelot (T)

Centre Léon Bérard, Lyon, France.

Mario Campone (M)

Inserm, U1232, Nantes, France.
Institut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, France.

Claudia Lefeuvre (C)

Centre Eugène Marquis, Rennes, France.

Herve Bonnefoi (H)

Institut Bergonié, Bordeaux, France.

Florence Dalenc (F)

Institut Claudius-Regaud, IUCT-oncopôle, Toulouse, France.

Alexandra Jacquet (A)

Unicancer, Paris, France.

Maria R De Filippo (MR)

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

Naveen Babbar (N)

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Daniel Birnbaum (D)

CRCM, Predictive Oncology team, Inserm, Aix-Marseille Univ, CNRS, Institut Paoli-Calmettes, Marseille, France.

Thomas Filleron (T)

Institut Claudius-Regaud, IUCT-oncopôle, Toulouse, France.

Christophe Le Tourneau (C)

Department of Drug Development and Innovation, Institut Curie, Saint-Cloud, France.
INSERM U900, Saint-Cloud, France.
Versailles Saint Quentin en Yvelines University, Montigny le Bretonneux, France.

Fabrice André (F)

Université Paris Sud, Orsay, France. fandre@igr.fr.
Inserm, Gustave Roussy Cancer Campus, UMR981, Villejuif, France. fandre@igr.fr.
Department of Medical Oncology, Gustave Roussy, Villejuif, France. fandre@igr.fr.

Classifications MeSH